Calumenin and fibulin-1 on tumor metastasis: Implications for pharmacology

  • Pharmacol Res. 2015 Sep;99:11-5. doi: 10.1016/j.phrs.2015.05.001.
Pengli Zheng  1 ,  Qiao Wang  1 ,  Junlin Teng  1 ,  Jianguo Chen  2
Affiliations
  • 1. State Key Laboratory of Bio-membrane and Membrane Bio-engineering; Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, College of Life Sciences, Peking University, Beijing 100871, China.
  • 2. State Key Laboratory of Bio-membrane and Membrane Bio-engineering; Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, College of Life Sciences, Peking University, Beijing 100871, China; Center for Quantitative Biology, Peking University, Beijing 100871, China. Electronic address: [email protected].
PMID: 25976680 DOI: 10.1016/j.phrs.2015.05.001
Abstract

Tumor metastasis is a key cause of Cancer mortality, and inhibiting migration of Cancer cells is one of the major directions of anti-metastatic drug development. Calumenin and fibulin-1 are two extracellular proteins that synergistically inhibit cell migration and tumor metastasis, and could potentially be served as targets for pharmacological research of anti-metastatic drugs. This review briefly introduces the multi-function of these two proteins, and discusses the mechanism of how they regulate cell migration and tumor metastasis.

Keywords
Anti-metastasis; Calumenin; Cell migration; Fibulin-1.
Products